A new systematic review and meta-analysis in eClinicalMedicine reminds us of something obesity researchers have been saying for decades. When obesity treatment stops, biology doesn’t. Yet the way many headlines frame these findings – “weight regain after GLP-1 drugs” – misses the deeper story. The paradigm of weight loss and regain is profoundly mistaken. It’s a way of thinking about obesity care that focuses mainly on losing weight. Not gaining health.

Across dozens of studies, investigators found a clear pattern after discontinuation of GLP-1 receptor agonists: weight tends to rebound, along with metabolic markers like HbA1c. On average, people regain a substantial portion of lost weight within a year of stopping treatment, though some benefit often persisted.

None of this should be shocking. What is truly surprising is that our common understanding of obesity is so shallow.

Grasping the Meaning  of a Chronic Disease

The science of obesity is clear. This is a chronic, relapsing disease driven by powerful biological systems that defend body weight. When pharmacotherapy affects appetite, improves satiety signaling, and alters metabolic regulation, it adjusts those systems. Remove the therapy, and the physiology resumes doing what it does on its own. It acts predictably to restore adiposity.

But the public conversation often frames this predictable physiology as a failure of “weight loss” rather than a challenge of chronic disease management.

Imagine applying the same logic elsewhere in medicine. If blood pressure rises after stopping antihypertensive therapy, no one declares that the treatment “didn’t work.” If glucose rises after stopping insulin, we don’t say the patient “regained diabetes.” We recognize the obvious: chronic diseases require ongoing care.

Obesity requires the same understanding.

A Mistaken Narrative

Focusing narrowly on weight loss and regain reinforces a mistaken narrative that treatment is temporary and success means reaching a goal weight and moving on. The science says otherwise. Like hypertension, asthma, or depression, obesity management often requires sustained therapy – sometimes behavioral, sometimes pharmacologic, sometimes surgical, and often a combination.

The new evidence about GLP-1 discontinuation doesn’t reveal a flaw in obesity medicines. It reveals the stubborn biology of obesity itself.

The real question is not why weight returns when treatment stops. The real question is why we still expect a chronic disease to behave like a short-term problem.

Click here for the study, here, here, and here for a sample reporting on it.

Elephant Gold Weight, photograph by The Brooklyn Museum, licensed under CC BY 3.0